Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug
03:40pm, Tuesday, 25'th Oct 2022
The biotech raised its earnings per share estimate to $16.50 to $17.15 from the previously estimated $15.25 to $16.75 range.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
03:03pm, Tuesday, 25'th Oct 2022
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
Biogen and Eisai make plans to take another Alzheimer's drug to the FDA
02:26pm, Tuesday, 25'th Oct 2022
Biogen Inc. BIIB, -2.03% and Eisai Co. Ltd. 4523, +3.57% are getting closer to possible approval of their new treatment for Alzheimer's disease, with plans to submit the drug for full Food and Drug Ad
Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript
09:57am, Tuesday, 25'th Oct 2022
Biogen Inc. (NASDAQ:BIIB ) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Michel Vounatsos - Chief Executive Officer Priya Sin
Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates
09:47am, Tuesday, 25'th Oct 2022
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Lifts Profit Estimates. The Stock Rises.
08:40am, Tuesday, 25'th Oct 2022
Biogen raised its earnings per share estimate to $16.50 to $17.15, up from the previously estimated $15.25 to $16.75 range.
Biogen beats revenue expectations in the third quarter
07:36am, Tuesday, 25'th Oct 2022
Biogen's BIIB, +2.62% stock was up 0.7% in premarket trading on Tuesday after it beat expectations for earnings and revenue in the third quarter of the year. The company had earnings of $1.1 billion,
Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect
12:02pm, Friday, 21'st Oct 2022
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
05:55am, Friday, 21'st Oct 2022
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.
Where Will Biogen Be in 5 Years?
10:07am, Thursday, 20'th Oct 2022
Is this biotech an investment worth buying and holding today?
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension
01:33pm, Tuesday, 18'th Oct 2022
The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.
Biogen's Stock Pullback Offers a Second Chance
02:01am, Tuesday, 18'th Oct 2022
Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive.
Biogen: How To Assess Lecanemab's Potential? Invert The Market's Reaction
04:56pm, Monday, 17'th Oct 2022
Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. From the reaction to Aduhelm's approval and option chain data, we see that the current stock price
FDA extends review time for Biogen's ALS treatment candidate
08:14am, Monday, 17'th Oct 2022
Shares of Biogen Inc. BIIB, -1.97% gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment fo
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity
09:45am, Saturday, 15'th Oct 2022
Let's break down how Biogen makes money right now and what's next for the company in light of some major news that surfaced recently about their new Alzheimer's treatment.
